DDInter557 DDInter204
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bicalutamide
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Rhinitis
Rhinitis {u} (Side Effect) is caused by {v} (Compound) Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enzalutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Bicalutamide
Dihydroergotamine {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Idarubicin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bicalutamide
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Dihydroergotamine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Bicalutamide (Compound)
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound) and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Dihydroergotamine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide
Dihydroergotamine (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Enzalutamide (Compound) and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Bicalutamide (Compound)
Dihydroergotamine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Idarubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide